NCT05373680View on ClinicalTrials.gov

Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Renal Insufficiency, Chronic
Interventions
DRUG

Metformin

Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

DRUG

Empagliflozin

Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

OTHER

Control

Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Trial Locations (2)

Unknown

Mansoura University, Al Mansurah

Tanta University Teaching Hospitals, Tanta

All Listed Sponsors
collaborator

Mansoura University

OTHER

lead

Tanta University

OTHER

NCT05373680 - Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression | Biotech Hunter | Biotech Hunter